Literature DB >> 11532538

S-100B is increased in melancholic but not in non-melancholic major depression.

M Rothermundt1, V Arolt, M Wiesmann, U Missler, M Peters, S Rudolf, H Kirchner.   

Abstract

BACKGROUND: Recent evidence suggests that neurodegeneration may be involved in the pathophysiology of major depression. The astroglial peptide S-100B was shown to be increased in many diseases causing neuronal cell damage or degeneration.
METHOD: S-100B plasma levels were determined in 28 patients with major depression and 28 matched healthy controls using an immunofluorometric sandwich assay.
RESULTS: Patients suffering from melancholic depression showed significantly increased S-100B levels compared to healthy controls while non-melancholic patients demonstrated normal levels. LIMITATIONS: Medication of patients varied. The differentiation between melancholic and non-melancholic patients was performed clinically without using a standardized instrument.
CONCLUSIONS: Neurodegeneration or axonal remodeling may be involved in the pathogenesis of melancholic depression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532538     DOI: 10.1016/s0165-0327(00)00321-9

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  23 in total

1.  Chronic fluoxetine treatment changes S100B expression during postnatal rat brain development.

Authors:  Nathalie Bock; Emre Koc; Hannah Alter; Veit Roessner; Andreas Becker; Aribert Rothenberger; Till Manzke
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-09-11       Impact factor: 2.576

2.  Elevated S100B and neuron specific enolase levels in patients with migraine-without aura: evidence for neurodegeneration?

Authors:  Nurgul Yilmaz; Kamil Karaali; Sebahat Ozdem; Mehtap Turkay; Ali Unal; Babur Dora
Journal:  Cell Mol Neurobiol       Date:  2011-02-04       Impact factor: 5.046

3.  The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression.

Authors:  Kun Yang; Guang-Rong Xie; Yi-Qiu Hu; Fu-Qiang Mao; Lin-Yan Su
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

4.  Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.

Authors:  R Bernard; I A Kerman; R C Thompson; E G Jones; W E Bunney; J D Barchas; A F Schatzberg; R M Myers; H Akil; S J Watson
Journal:  Mol Psychiatry       Date:  2010-04-13       Impact factor: 15.992

5.  Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model.

Authors:  Lee A Shapiro; Lynn A Bialowas-McGoey; Patricia M Whitaker-Azmitia
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-22

6.  The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.

Authors:  Guenter Hetzel; Olaf Moeller; Stefan Evers; Andreas Erfurth; Gerald Ponath; Volker Arolt; Matthias Rothermundt
Journal:  Psychopharmacology (Berl)       Date:  2004-08-14       Impact factor: 4.530

Review 7.  Toll-Like Receptor Signaling in Depression.

Authors:  Leandra K Figueroa-Hall; Martin P Paulus; Jonathan Savitz
Journal:  Psychoneuroendocrinology       Date:  2020-09-01       Impact factor: 4.905

8.  Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation.

Authors:  Jennifer L Warner-Schmidt; Marc Flajolet; Abigail Maller; Emily Y Chen; Hongshi Qi; Per Svenningsson; Paul Greengard
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 9.  Functions of S100 proteins.

Authors:  R Donato; B R Cannon; G Sorci; F Riuzzi; K Hsu; D J Weber; C L Geczy
Journal:  Curr Mol Med       Date:  2013-01       Impact factor: 2.222

10.  Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response.

Authors:  Byong-Su Jang; Hyeran Kim; Shinn-Won Lim; Ki-Won Jang; Doh-Kwan Kim
Journal:  Psychiatry Investig       Date:  2008-09-30       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.